Market Dynamics
The global market for adult-onset Growth Hormone Deficiency (GHD) is projected to exhibit a rapid revenue Compound Annual Growth Rate (CAGR) throughout the forecast period. This growth is driven by the increased efforts from both public and private organizations to raise awareness about GHD and the potential market expansion associated with growth hormone therapy.
Get a sample copy of the Adult Onset Growth Hormone Deficiency (GHD) Treatment Market report: https://www.reportsanddata.com/download-free-sample/5668
Geographic Market Overview
Region with the Largest Revenue Share: North America is expected to dominate the market during the forecast period, driven by a growing number of research projects, the presence of key players, and rising healthcare costs.
Region with the Fastest Revenue Growth Rate: The Asia Pacific region is anticipated to experience the fastest growth due to the expansion of healthcare infrastructure and an increasing elderly population.
Report Highlights and Distinctive Features
Organic and Inorganic Strategies Adopted
Since October 2019, the Center for Neurological Studies has collaborated with Novo Nordisk A/S in a Phase II clinical trial study to assess the effectiveness of GHD on the cognitive functioning of former professional football players with growth hormone deficiency.
Adult-onset Growth Hormone Deficiency is a medical condition characterized by insufficient production of growth hormone by the anterior pituitary gland in the brain. This hormone stimulates the release of Insulin-like Growth Factor 1 (IGF-1), primarily produced by the liver. These hormones play vital roles in physical development, mental well-being, and height growth in both children and adults. GHD also has profound metabolic effects on the entire body.
Drivers:
- The increased prevalence of growth disorders and heightened public awareness regarding the use of synthetic growth hormone therapy are significant factors propelling market revenue growth. The number of reported cases of growth disorders has increased due to extensive research into their root causes and improved diagnosis rates. These disorders encompass low growth hormone levels in children and adults, idiopathic short stature, and inherited conditions like Turner syndrome and Prader-Willi syndrome.
- The rise in healthcare spending, which supports infrastructure development, is a pivotal driver of revenue growth in the growth hormone deficiency market. Government organizations’ efforts to bolster healthcare infrastructure through increased funding will further influence market dynamics. The market for growth hormone deficiencies will also benefit from public and private initiatives aimed at raising awareness. Changing lifestyles and an increased incidence of hereditary diseases will also contribute to the growth of the adult-onset growth hormone deficiency market.
Restraints:
- High treatment costs are a limiting factor in market revenue growth. The market for treating adult-onset growth hormone insufficiency faces challenges in underdeveloped nations due to a shortage of qualified healthcare personnel and inadequate healthcare infrastructure. Stringent regulatory requirements and limited public awareness act as restraints on market growth.
Opportunities:
- Increased research and development activities and a greater number of drug releases and approvals will foster market expansion.
- Investments in cutting-edge technologies and the emergence of new markets during the forecast period will further support the growth of the adult-onset growth hormone deficiency market.
Most cases of adult-onset GHD are caused by pituitary tumors or their treatment through surgery, radiotherapy, or a combination of both. Additionally, other types of growth hormone insufficiency can result from fetal pituitary gland abnormalities or genetic disorders like Prader-Willi syndrome or Turner syndrome. GHD is typically detected in infancy or early childhood, but treatment may also be necessary for adults. Factors Contributing to Market Growth
Key Market Trends and Innovations
- Since December 2021, Ascendis Pharma Endocrinology Division A/S has been conducting a Phase III clinical trial investigation to evaluate the long-term safety and effectiveness of Lonapegsomatropin when administered once-weekly to adults with proven growth hormone deficiency.
- A Phase III clinical trial study initiated in December 2020 by Ascendis Pharma Endocrinology Division A/S aims to compare the effectiveness and safety of once-weekly Lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency.
Major Companies in the Market
Key players in the market include GlaxoSmithKline Plc., Pfizer Inc., Novo Nordisk A/S, and Ascendis Pharma A/S.
Scope of the Report
The report covers various aspects including product types (tablets, capsules, injectables, and others), route of administration (oral, parenteral, and others), disease types (partial, complete, and others), distribution channels (online and offline), and end-users (hospital pharmacy, retail pharmacy, specialty clinics). The regional outlook includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with specific country-level data.
Explore Trending Reports:
Polysorbate Market-https://www.globenewswire.com/news-release/2019/09/09/1913005/0/en/Polysorbate-Market-To-Reach-USD-1-478-0-Million-By-2026-Reports-And-Data.html
Cyclopentane Market-https://www.globenewswire.com/news-release/2019/11/18/1948841/0/en/Cyclopentane-Market-To-Reach-USD-400-3-Million-By-2026-Reports-And-Data.html
Quats (Quaternary Ammonium Compounds) Market-https://www.globenewswire.com/news-release/2020/05/18/2035231/0/en/Quats-Quaternary-Ammonium-Compounds-Market-To-Reach-USD-1-63-Billion-By-2027.html#:~:text=New%20York%2C%20May%2018%2C%202020,report%20by%20Reports%20and%20Data.
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5668
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data   Â
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web:Â www.reportsanddata.com
Direct Line:Â +1-212-710-1370
E-mail:Â sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @Â https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release
